Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Renal Insufficiency 3Kidney Failure, Chronic 3Multiple Myeloma 2Carcinoma, Renal Cell 2Virus Diseases 1Renal Insufficiency, Chronic 1Kidney Diseases 1Hematologic Neoplasms 1Graft vs Host Disease 1Epstein-Barr Virus Infections 1

Interventions

Sunitinib 145Nivolumab 144pembrolizumab 132Sorafenib 84Bevacizumab 77Everolimus 74cabozantinib 71pazopanib 65Axitinib 65Ipilimumab 62aldesleukin 52Magnetic Resonance Spectroscopy 45Cyclophosphamide 40Interleukin-2 38lenvatinib 37Specimen Handling 36Radiosurgery 36Interferon-alpha 32atezolizumab 30temsirolimus 27belzutifan 24Gemcitabine 23fludarabine phosphate 22avelumab 22Radiotherapy 19Interferon alpha-2 19Biopsy 18fludarabine 17durvalumab 17Nephrectomy 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Kidney Transplantation × Clear all
NCT05725421 2026-05-28

Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy

Case Comprehensive Cancer Center

Phase NA Withdrawn
Genitourinary

Carcinoma, Renal Cell

NCT07053462 2025-07-08

CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Failure, Chronic, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡